Clinical utility of Cerebrospinal fluid Aꞵ42 and tau measures in diagnosing mild cognitive impairment in early onset dementia

Manuscript Number: 

21-5650R1

Author(s): 
Thomas Brown, Bruno Gran, Akram A. Hosseini, Kehinde Junaid, Luca Mannino, Elizabeta B. Mukaetova-Ladinska

Disclosures

Thomas Brown

  • Nothing to Disclose

Bruno Gran

  • Consulting Fees:
    In the last two years, I have received personal compensation for consultancy from Roche, and GW Pharma, and support for the attendance of clinical and research conferences Novartis and CelGene.
    Grants
    • Agency: 
      Unrestricted research grant from Roche
      Dates: 
      4/2021 - 3/2023

Akram A. Hosseini

  • Nothing to Disclose

Kehinde Junaid

  • Nothing to Disclose

Luca Mannino

  • Nothing to Disclose

Elizabeta B. Mukaetova-Ladinska

  • Nothing to Disclose